Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors

Solid Tumor, Unspecified, Adult Clinical Trial

Official title:

Phase 1/2a Dose-ranging, Safety, Pharmacokinetics, and Preliminary Efficacy Study of MPB-1734 in Patients With Advanced Solid Tumors in Part 1 and With Selected Solid Tumors in Part 2

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04643418
• Other study ID #: DMB-CT-001
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: March 8, 2022
• Est. completion date: December 2025

Study information

• Verified date: April 2022
• Source: MegaPro Biomedical Co. Ltd.
• Contact: Summer Liao, MS
• Phone: +886-3-5910360
• Email: thliao[@]megaprobio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1/2a study with dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15 patients per selected indication (Part 2). The solid tumor types in Part 2 will be decided by the sponsor prior to the start of Part 2, but not be solely based on the efficacy results in Part 1.

Description:

This study will occur in two parts, Dose-escalation (Part 1) and Cohort-expansion (Part 2). The main purpose of Part 1 is to determine the doses and dosing schedule of MPB-1734 that is safe and tolerable when given in subjects with certain types of advanced cancer. Part 2 of the study will begin when the Sponsor determines the safe and tolerable doses and dosing schedule from Part 1. The main purpose of Part 2 is to continue to assess the safety and tolerability of the MPB-1734 dose and dosing schedule determined by the Sponsor during Part 1. The preliminary efficacy of MPB-1734 will also be assessed in both Part 1 and Part 2.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 81
• Est. completion date: December 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent in the local language prior to any study-mandated procedure.

2. Male or female patients at least 18 years of age, at the time of informed consent.

3. Male or nonpregnant and nonlactating female patients with pathologically confirmed, measurable solid tumor lesions (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]) that are unresectable, and standard therapy able to provide clinical benefit does not exist or is no longer effective.

4. Eastern Cooperative Oncology Group Performance Status =2.

5. Patients have recovered from the acute toxicity of previous therapies (peripheral sensory neuropathy recovered to =Grade 2) except alopecia, and:

• At least 4 weeks have elapsed since completing surgery, endocrine therapy, tyrosine kinase inhibitor therapy, immunotherapy, radiotherapy, chemotherapy, and/or

• At least 6 weeks have elapsed since completing chemotherapy with nitrosoureas, melphalan, and/or mitomycin C, and/or

• At least 6 weeks have elapsed since completing cranial radiotherapy.

6. Life expectancy of greater than 12 weeks.

7. Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study.

Exclusion Criteria:

1. Peripheral sensory neuropathy >Grade 2 (CTCAE version 5.0) at baseline.

2. Patients requiring immediate palliative treatment of any kind including surgery and/or radiotherapy.

3. Serum bilirubin >1.5× ULN.

4. AST and/or ALT >2.5× ULN if no liver involvement, OR AST and/or ALT >5× ULN with liver involvement.

5. Serum creatinine >1.5× ULN, and/or a creatinine clearance of <50 mL/min calculated by Cockcroft Gault.

6. QTc prolongation defined as a QTc with Framingham correction greater than or equal to 470 ms, or significant electrocardiogram (ECG) abnormalities.

7. Known hypersensitivity to taxanes or any excipients of the drug formulation.

8. Female patients who are pregnant, breast-feeding, or planning to become pregnant during the study.

9. Untreated and/or uncontrolled central nervous system metastases.

10. Patients with brain tumors, primary or metastatic.

11. Patients taking concomitant medications anticipated to result in drug-drug interactions.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor, Unspecified, Adult

Intervention

Drug:
• MPB-1734
Administered once daily in a 21-day cycle

Locations

Country	Name	City	State
Taiwan	Taipei Veterans General Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
MegaPro Biomedical Co. Ltd.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation the the maximum tolerated dose(MTD) by safety data	Number and incidence of (serious) adverse events (AEs) ([S]AEs), including rate of mild, moderate, and severe hypersensitivity reactions, fluid retention, and sensory neuropathy an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle.	Through the end of the first cycle (Days 1-21).
Secondary	Incidence of Treatment-Emergence Adverse Events	Each adverse event will be coded using the Medical Dictionary (version 20.0) system. The severity of the toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).	Approximately 24 weeks
Secondary	Maximum observed plasma concentration (Cmax)	Evaluation the change of Cmax	Day 1-Day 2
Secondary	Area under the plasma concentration-time curve (AUC)	Evaluation the change of AUC	Day 1-Day 2
Secondary	Half-life (T1/2)	Evaluation of T1/2	Day 1-Day 2